MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients
Chang et al. 1 reported the frequent expression of C-Maf nuclear oncoprotein in multiple myeloma (MM), not only in patients positive for the t(14;16) (q32;q23), which results in an upregulation of C-Maf, but also in a considerable proportion (25%) of t(14;16)-negative patients. Here, we have studied MafB oncoprotein expression in MM patient samples, starting with samples tested for the t(14;20) (q32;q12) by fluorescence in situ hybridization (FISH) analysis. 2 As a result, we only found protein expression of MafB confined to t(14;20)-positive patients. This is remarkable, as primary translocations involving MafB and CMaf are grouped together according their expression and correlation of high CYCLIN D2 activity and poor prognosis in MM (reviewed in Chng et al. 3 ). As a result of the t(14;20) translocation, MafB is translocated to the immunoglobulin (Ig) heavy chain locus on chromosome 14, juxtaposed to the strong IgH-Ea enhancer, resulting in oncogenic overexpression of MafB. Primary translocations are major events in MM with a prevalence of about 40%.
Maf genes form a distinct group of bZIP (basic leucine zipper) transcription factors and belong to the AP-1 super family. Members from the large Maf group can form homo-and heterodimers with other members of bZIP transcription factors 3 ) In this study, we developed a specific anti-MafB monoclonal antibody to detect MafB protein expression in primary MM tumor samples, as tested by immunohistochemistry (IHC) in two independent MM patient data sets. The first data set represented a total of 73 patients diagnosed with MM treated in the University Medical Center Utrecht. The median age was 57 years and represents 46 male and 27 female patients. In all, 40 patients had an IgG M protein, 16 IgA and one IgD, one IgM and 15 light chain disease. Twenty patients of this data set were previously screened for t(14;20) by FISH analysis and two patients carried this t(14;20). 2 In these particular patients, the tumors were very progressive and one patient died after 13 months. 5 From 53 patients, the cytogenetic background with respect to Maf was not known at the time of staining. The second data set represented 2 MM (two female) patients tested positive for t(14;20) by FISH analysis and four (three male, one female) MM patients not harboring a t(14;20). The median age was 60 years and four patients had an IgG M protein, one IgA and one light chain disease. These patients were diagnosed and treated in UCL Mont-Godinne, Brussels, Belgium.
The anti-MafB monoclonal antibody was raised as described previously. 6 A 971-bp PCR product encoding all amino acids of the full human MafB coding region was used to produce recombinant protein in Escherichia coli and used for mouse immunizations. Four hybridomas were isolated that recognized full-length human MafB, when overexpressed in COS cells, and the best one (clone 1F4, IgG1k) performed well in western Blot analysis and immunofluorescence ( Figure 1 ).
For detection of MafB protein by IHC, this antibody was tested and proved positive on both formalin-and Bouin-fixed cells obtained from the MafB-positive UM3, L363 and UM6 MM cell lines 5 (data not shown); this was tested as bone marrow biopsies from both data sets were fixed differently, for example, formalin fixation in the University Medical Center Utrecht and Bouin fixation in UCL Mont-Godinne, Brussels. Paraffin sections were deparaffinizated and heat induced for antigen retrieval. Nonimmune mouse serum was tested as negative control. Paraffin sections of the U-266 and RPMI-8226MM cell lines stained negative (data not shown), confirming the western blotting.
From diagnostic bone marrow biopsy blocks, 5 mM thick paraffin sections were cut and stained for plasma cell detection and MafB expression. MafB is responsible for monocyte/ macrophage differentiation in the hematopoetic system, 7 and the expression of MafB in monocytes and macrophages (identified according to CD68 expression, data not shown) served as a positive control within bone marrow tissue samples.
Myeloma cells of all samples tested from both data sets were detected on the basis of positivity for cytoplasmatic light chain staining. Two independent observers estimated the percent of MafB protein-stained nuclei. Cases with more than 20% MafB nuclear expression were considered positive.
In all 20 MM patient samples from the first data set, which had been tested for t(14;20), MafB nuclear expression was only observed in the plasma cells (470%) from the two t(14;20)-positive patients (Figure 2 ). In patients not carrying the t(14;20), no nuclear MafB expression was detected in the plasma cells, both indicating the specificity of the anti-MafB monoclonal antibody, as well as the restricted presence of MafB in t(14;20)-positive patients. Next, we studied MafB expression in 53 randomly chosen MM patients from this first data set not knowing the cytogenetic background. As a result, one of the 53 patient samples was positive for MafB. In review, cytogenetic studies on cultured cells derived from peripheral blood of this patient diagnosed for plasma cell leukemia had resulted in a 44,XX,del (6)(q21),del (12)(p12),-13,add(14)(q32),-16,-20, þ mar[18]/46,XX [10] karyotype. FISH analysis using whole chromosome 14 and 20 specific paints revealed a derivative chromosome 14 as a result of a t(14;20) with loss of derivative chromosome 20 (Figure 3) . FISH analysis using a 14q32 IgHspecific probe showed a 14q32 IgH rearrangement with loss of telomeric 5
0 IgH variable gene segments in accordance with the absence of derivative chromosome 20 (probe: LSI IgH, Abbott Molecular Inc., Des Plaines, IL, USA; data not shown). 
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After analyzing samples from the second data set, the two MafB-positive MM patients according to the t(14;20), MafB oncoprotein expression was also found in 470% of the plasma cells, whereas the t(14;20)-negative MM patients in the same data set scored negative for MafB protein. In conclusion, MafB oncoprotein expression in MM patients is strongly correlated with t(14;20).
Interestingly, in one MafB-positive patient, we could detect 1% MafB-positive plasma cells after VAD therapy (data not shown), which might suggest that this staining may be used as a marker for minimal residual disease (MRD).
Taken together, this is the first report to detect MafB oncoprotein expression in MM patients. MafB upregulation because of the t(14;20) coincides with an adverse outcome; here, we show that the protein was detected exclusively in patients carrying this t(14;20). This resembles the strong correlation between t(4;14), a primary translocation resulting in the overexpression of FGFR3 in MM, detected by interphase FISH and FGFR3 protein expression by IHC in MM. 8 Our results seem to be at variance with data on the C-Maf protein, which the expression was detected in 30% of MM cases regardless of harboring a t(14;16). 1 Our results here and the restricted FGFR3 expression in MM 8 arouse the question why C-Maf expression has been found in such a higher proportion of MM patients, and what would be its significance, especially as in that study no prognostic impact could be attributed to the C-Maf oncoprotein expression. One factor in this aspect may be that (contrary to the polyclonal anti-C-Maf antibody used by Chang et al.,
1 but in concordance with the monoclonal anti-FGFR3 antibody used by Chang et al. 8 ) we have used a monoclonal anti-MafB antibody here; indeed, comparatively we have been using a polyclonal anti-MafB antibody, but these results were not fully evaluable for us (data not shown). Furthermore, recently, the high proportion of C-Maf mRNA overexpression found by quantitative real-time PCR (50% of MM bone marrow samples 9 ) has been questioned. Rasmussen et al.
10 also found C-Maf mRNA, by quantitative real-time PCR, being overexpressed in only 4.4% in MM patients, coinciding with the reported prevalence of t(14;16) in MM, that is, B5% (reviewed in Chng et al. 3 ). Altogether, these data suggest that the prevalence of C-Maf oncoprotein expression in MM remains a matter of debate.
Because we show that aberrant MafB expression detection with paraffin ICH is an easy and reliable method, we suggest that our anti-MafB monoclonal antibody may be used in routine diagnostic matters. Indeed, as MafB protein detection was only found in patients carrying t(14;20) (which is associated with a bad prognosis), our results indicate that MafB may be a prognostic marker in the risk stratification of MM patients.
Importantly, the exclusive presence of MafB protein associated with this adverse prognosis may enable novel therapies targeting the MafB gene expression pathway. Indeed, for expression of FGFR3, it has been demonstrated that inhibition of FGFR3 by an inhibitory anti-FGFR3 antibody inhibits proliferation and induces apoptosis in FGFR3-expressing human myeloma cells. 
